BMP type I receptor inhibition reduces heterotopic ossification

被引：522

作者：

Yu P.B. ^{[1
,2
]}

Deng D.Y. ^{[1
]}

Lai C.S. ^{[1
]}

Hong C.C. ^{[3
]}

Cuny G.D. ^{[4
]}

Bouxsein M.L. ^{[5
]}

Hong D.W. ^{[1
]}

McManus P.M. ^{[1
]}

Katagiri T. ^{[6
]}

Sachidanandan C. ^{[1
]}

Kamiya N. ^{[7
]}

Fukuda T. ^{[7
]}

Mishina Y. ^{[7
,8
]}

Peterson R.T. ^{[1
]}

Bloch K.D. ^{[1
,2
]}

机构：

[1] Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston

[2] Anesthesia Centre for Critical Care Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, Thier 505

[3] Division of Cardiovascular Medicine, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232

[4] Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139

[5] Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215

[6] Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, Hidaka-shi, Saitama 350-1241

[7] Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709

[8] Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI 48109

来源：

Nature Medicine | 2008年 / 14卷 / 12期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1038/nm.1888

中图分类号：

学科分类号：

摘要：

Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread postnatal ossification of soft tissues and is without known effective treatments. Affected individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2 (ALK2). Here we show that intramuscular expression in the mouse of an inducible transgene encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional impairment, thus phenocopying key aspects of human FOP. A selective inhibitor of BMP type I receptor kinases, LDN-193189 (ref. 6), inhibits activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in tissues expressing caALK2 induced by adenovirus specifying Cre (Ad.Cre). This treatment resulted in a reduction in ectopic ossification and functional impairment. In contrast to localized induction of caALK2 by Ad.Cre (which entails inflammation), global postnatal expression of caALK2 (induced without the use of Ad.Cre and thus without inflammation) does not lead to ectopic ossification. However, if in this context an inflammatory stimulus was provided with a control adenovirus, ectopic bone formation was induced. Like LDN-193189, corticosteroid inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and an inflammatory milieu are both required for the development of ectopic ossification in this model. These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small molecule inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes associated with excessive BMP signaling. © 2008 Nature Publishing Group.

引用

页码：1363 / 1369

页数：6

共 33 条

[1]

Shore E.M., Kaplan F.S., Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP), Bone, 43, pp. 427-433, (2008)

[2]

Buyse G., Silberstein J., Goemans N., Casaer P., Fibrodysplasia ossificans progressiva: Still turning into wood after 300 years?, Eur. J. Pediatr, 154, pp. 694-699, (1995)

[3]

Kaplan F.S., Glaser D.L., Pignolo R.J., Shore E.M., A new era for fibrodysplasia ossificans progressiva: A druggable target for the second skeleton, Expert Opin. Biol. Ther, 7, pp. 705-712, (2007)

[4]

Kaplan F.S., Et al., Fibrodysplasia ossificans progressiva, Best Pract. Res. Clin. Rheumatol, 22, pp. 191-205, (2008)

[5]

Shore E.M., Et al., A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva, Nat. Genet, 38, pp. 525-527, (2006)

[6]

Cuny G.D., Et al., Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors, Bioorg. Med. Chem. Lett, 18, pp. 4388-4392, (2008)

[7]

Tsuchida K., Mathews L.S., Vale W.W., Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor, Proc. Natl. Acad. Sci. USA, 90, pp. 11242-11246, (1993)

[8]

Miyazono K., Maeda S., Imamura T., BMP receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk, Cytokine Growth Factor Rev, 16, pp. 251-263, (2005)

[9]

Groppe J.C., Shore E.M., Kaplan F.S., Functional modeling of the ACVR1 (R206H) mutation in FOP, Clin. Orthop. Relat. Res, 462, pp. 87-92, (2007)

[10]

Shore E.M., Xu M., Connor J.M., Kaplan F.S., Mutations in the BMP type I receptor ACVR1 in patients with fibrodysplasia ossificans progressiva (FOP), J. Bone Miner. Res, 21, (2006)

← 1 2 3 4 →